QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 transcode-therapeutics-and-michigan-state-target-metastatic-breast-cancer-in-new-study

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA th...

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

 new-research-published-in-oncotarget-shows-inhibition-of-mir-10b-with-mn-anti-mir10b-nanodrug-targets-stem-cell-like-properties-in-metastatic-breast-cancer-reducing-stemness-and-preventing-metastasis-in-mouse-models-when-combined-with-chemotherapy

https://www.eurekalert.org/news-releases/1055915

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

 transcode-therapeutics-13g-filing-shows-3i-lp-reported-a-99-stake-in-the-co-as-of-july-23-2024

- SEC Filing

 transcode-therapeutics-files-for-offering-of-up-to-10m-shares-of-common-stock

- SEC Filing

 why-transcode-therapeutics-rnaz-stock-is-down-60

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its publi...

 reported-earlier-transcode-therapeutics-prices-3m-public-offering-of-10m-common-shares-at-030share

The Company intends to use the net proceeds from the offering primarily for product development activities, including one or mo...

 transcode-therapeutics-has-regained-compliance-with-nasdaqs-continued-listing-requirements

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), (the "Company"), an RNA oncology company committed to more effectively trea...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION